Oct 26, 2020 / 12:00PM GMT
Operator
Greetings, and welcome to the Crinetics Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Corey Davis. Thank you. You may begin.
Corey Davis -
Thanks, Melissa, and thank you all for participating in today's call. Earlier this morning, Crinetics issued a news release announcing positive top line data from its Phase II ACROBAT EDGE and EVOLVE trials. If you've not yet seen the release, it's available on the Investors section of the Crinetics Pharmaceuticals website.
Before we begin, I'd like to remind you that some of the information contained in the news release and on this call contains forward-looking statements based on current expectations, including statements about the initiation of planned clinical trials. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the
Crinetics Pharmaceuticals Inc Review Of Phase 2 Paltusotine Results Call Transcript
Oct 26, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers